For research use only. Not for therapeutic Use.
Efinaconazole (Cat No.: I002153) is the first topical triazole antifungal drug developed for the treatment of local distal lateral subungual fungus (DLSO). Efinaconazole is also an inhibitor of 14 alpha-demethylase. 14 alpha-demethylase is involved in the biosynthesis of ergosterol, a component of the fungal cell membrane.
| Catalog Number | I002153 |
| CAS Number | 164650-44-6 |
| Synonyms | (2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylidenepiperidin-1-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol |
| Molecular Formula | C18H22F2N4O |
| Purity | ≥95% |
| Target | Antifungal |
| Solubility | 10 mM in DMSO |
| Storage | -20°C |
| IC50 | 0.0039 ug/ml (MIC for T. mentagrophytes SM-110) [1] |
| IUPAC Name | (2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylidenepiperidin-1-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol |
| InChI | InChI=1S/C18H22F2N4O/c1-13-5-7-23(8-6-13)14(2)18(25,10-24-12-21-11-22-24)16-4-3-15(19)9-17(16)20/h3-4,9,11-12,14,25H,1,5-8,10H2,2H3/t14-,18-/m1/s1 |
| InChIKey | NFEZZTICAUWDHU-RDTXWAMCSA-N |
| SMILES | CC(C(CN1C=NC=N1)(C2=C(C=C(C=C2)F)F)O)N3CCC(=C)CC3 |
| Reference | </br>1:Efinaconazole solution 10% for treatment of toenail onychomycosis in Latino patients. Cook-Bolden FE, Lin T.Cutis. 2017 Apr;99(4):286-289. PMID: 28492600 </br>2:Onychomadesis caused by efinaconazole. Yamaguchi Y, Hoshina D, Furuya K.Contact Dermatitis. 2017 Jan;76(1):57-58. doi: 10.1111/cod.12658. No abstract available. PMID: 27957751 </br>3:Allergic contact dermatitis caused by efinaconazole: positive patch test reactions up to 0.1% pet. Oiso N, Tatebayashi M, Kawada A.Contact Dermatitis. 2017 Jan;76(1):53-54. doi: 10.1111/cod.12643. No abstract available. PMID: 27957750 </br>4:Update on Efinaconazole 10% Topical Solution for the Treatment of Onychomycosis. Gupta AK, Studholme C.Skin Therapy Lett. 2016 Nov;21(6):7-11. PMID: 27825175 Free Article</br>5:Efinaconazole 10% and Tavaborole 5% Penetrate Across Poly-ureaurethane 16%: Results of In Vitro Release Testing and Clinical Implications of Onychodystrophy in Onychomycosis. Adigun CG, Vlahovic TC, McClellan MB, Thakker KD, Klein RR, Elstrom TA, Ward DB.J Drugs Dermatol. 2016 Sep 1;15(9):1116-20. PMID: 27602975 </br>6:Ungual aspergillosis successfully treated with topical efinaconazole. Noguchi H, Hiruma M, Matsumoto T, Kano R, Ihn H.J Dermatol. 2016 Aug 11. doi: 10.1111/1346-8138.13543. [Epub ahead of print] No abstract available. PMID: 27511741 </br>7:JUBLIA (Efinaconazole): An Update. Gupta AK, Cernea M, Abramovits W.Skinmed. 2016 Jun 1;14(3):207-9. eCollection 2016. No abstract available. PMID: 27502259 </br>8:Tavaborole, Efinaconazole, and Luliconazole: Three New Antimycotic Agents for the Treatment of Dermatophytic Fungi. Saunders J, Maki K, Koski R, Nybo SE.J Pharm Pract. 2016 Aug 3. pii: 0897190016660487. [Epub ahead of print] PMID: 27488125 </br>9:Successful Treatment of Paecilomyces lilacinus Onychomycosis with Efinaconazole and Tavaborole. Evans JM, Wang AL, Elewski BE.Skin Appendage Disord. 2016 May;1(4):169-71. doi: 10.1159/000443773. Epub 2016 Feb 5. PMID: 27386459 Free PMC Article</br>10:Onychomycosis of Toenails and Post-hoc Analyses with Efinaconazole 10% Solution Once-daily Treatment: Impact of Disease Severity and Other Concomitant Associated Factors on Selection of Therapy and Therapeutic Outcomes. Del Rosso JQ.J Clin Aesthet Dermatol. 2016 Feb;9(2):42-7. PMID: 27047631 Free PMC Article |
